GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InnoCare Pharma Ltd (FRA:33C) » Definitions » Accounts Receivable

InnoCare Pharma (FRA:33C) Accounts Receivable : €35.55 Mil (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is InnoCare Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. InnoCare Pharma's accounts receivables for the quarter that ended in Dec. 2023 was €35.55 Mil.

Accounts receivable can be measured by Days Sales Outstanding. InnoCare Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 was 125.54.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. InnoCare Pharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was €0.42.


InnoCare Pharma Accounts Receivable Historical Data

The historical data trend for InnoCare Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InnoCare Pharma Accounts Receivable Chart

InnoCare Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Accounts Receivable
Get a 7-Day Free Trial 0.01 0.02 6.29 17.33 35.55

InnoCare Pharma Quarterly Data
Dec17 Sep18 Dec18 Jun19 Sep19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Jun23 Sep23 Dec23 Mar24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 17.33 25.19 22.79 35.55 -

InnoCare Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


InnoCare Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

InnoCare Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=35.546/25.836*91
=125.54

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), InnoCare Pharma's accounts receivable are only considered to be worth 75% of book value:

InnoCare Pharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1056.267+0.75 * 35.546+0.5 * 15.295-351.69
-0-4.22)/1763.13
=0.42

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


InnoCare Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of InnoCare Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCare Pharma (FRA:33C) Business Description

Traded in Other Exchanges
Address
No. 8 Life Science Park Road, Building 8, Zhongguancun Life Science Park, Changping District, Beijing, CHN, 102206
InnoCare Pharma Ltd is a commercial-stage biopharmaceutical company. It discovers, develops, and commercializes drugs for the treatment of cancer and autoimmune diseases. The company's main product pipeline includes orelabrutinib, ibrutinib, zanubrutinib, tafasitamab, ICP-490, ICP-B02, ICP-248, ICP-192, ICP-723, and ICP-189, among others. Its products are mainly used to treat hematological tumors, solid tumors, and autoimmune diseases. The company is also developing products for the treatment of autoimmune diseases caused by abnormal B-cell or T-cell function.

InnoCare Pharma (FRA:33C) Headlines

No Headlines